Cost avoidance related to a pharmacist-led pharmacogenomics service for the Program of All-inclusive Care for the Elderly

Clinical Evidence | 1 Minute Read

By: Kevin T Bain , Calvin H Knowlton & Adriana Matos


Aim: Estimate cost avoidance of pharmacist recommendations for participants enrolled in the Program of All-inclusive Care for the Elderly.

Materials & methods: Convenience sample of 200 pharmacogenomics consultations from the PHARM-GENOME-PACE study. Genetic variants, drug–gene interactions, drug–drug–gene interactions and phenoconversions were interrogated. Cost avoidance was estimated and adjusted for inflation.

Results: In total, 165 participants had at least one actionable drug–gene pair totaling 429 drug–gene pairs, of which 158 (36.8%) were clinically actionable. Most (70.5%) pharmacists’ recommendations were accepted. Estimated cost avoidance was $233,945 when all recommendations were included but conservatively $162,031 based on acceptance rates. Overall mean cost avoidance per actionable drug–gene pair was $1063 or $1983 per participant.

Conclusion: Pharmacist-led pharmacogenomics services added to the traditional medication review can avoid substantial costs for payers.

Share this:
Fill 1 Copy 2closeFill 5 Copy 4green-arrowhamburgerFill 7 Copy 4Fill 1 Copy 4pauseplaysearch-iconFill 3 Copy 4